

- Pratibha Industries secures a contract for construction of Tunnel for transporting water from Municipal Corporation of Brihanmumbai worth Rs1.57bn
 - Aurobindo Pharma has US FDA approved its Zolpidem tablets in strengths 5mg and 10mg. Zolpidem enjoys a market of around \$2.1 billion in the USA
 - J&K Bank net profit of Rs 452.80mn (up 99%), income Rs5.75bn (up 17%) and dividend at Rs11 per share
 - Mphasis may win \$100-150 oversea contract - CNBC
 - Maruti introduce new SX4 model to cost at Rs6.18 lakh
 - Ashok Leyland April sales up by 16% (YoY) at 5849
 - Union Bank Q4 net profit Rs2.29bn (up 58%) and income Rs23.37bn (up 34%)
 - RCF net profit Rs 333.10mn (down 58%) and Rs95bn (up 10%)
 - Gail India - Dabhol Power Plant towards revival with the commissioning of the first stretch of Dahej - Panvel - Dabhol Pipeline
 - Tech Mahindra Q4 net profit Rs1.96bn (up 17.5% QoQ) and income Rs8.75bn (up 13.6% QoQ)
- LME:**
- Metal price continued to northbound journey due to declined inventory. Copper price has gained by 1.6% followed by Aluminum and Zinc price gained by 1.5% and 3.5% respectively
- Global Market:**
- Asian stocks climbed to a record on expectations earnings from Japan Airlines Corp. and Tokyo Electron Ltd. will beat forecasts. Nikkei gained by 1.6% followed by Hang Sang and China market surged by 0.3% and 2.2% respectively.
 - European stocks recovered partially from lower levels after Alcoa Inc., the world's largest aluminum company, said it plans to offer cash and stock valued at \$33 billion to acquire Alcan Inc. Both Dax and CAC have gained marginally against previous day's close.
- Institutional activities:**
- | | | |
|---------------|---|-----------------|
| 04 May | : | Rs (Cr.) |
| FII (Cash) | : | N.A. |
| FII (F&O) | : | -209.00 |
| MFs | : | N.A. |

Disclaimer: This report is for the personal information of the authorized recipient and does not constitute to be any investment, legal or taxation advice to you. Motilal Oswal Securities Limited (hereinafter referred as MOST) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. "The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon such. MOST or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOST or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations." MOST and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report."